Monument Therapeutics Announces Leadership Changes
Company - People | Apr 28, 2025 | Catapult Ventures Group
Monument Therapeutics, a company specializing in precision neuroscience, has made two significant leadership appointments. Robert S. Radie, known for his experience in biotech, is appointed as Non Executive Chair. Additionally, Dr. Heather Preston is joining the Advisory Board, bringing her extensive background in healthcare and investment. The moves are backed by Catapult Ventures Group, a prominent private equity firm investing in innovative healthcare solutions. Monument Therapeutics focuses on addressing central nervous system disorders with innovative treatments.
Sectors
- Biotechnology
- Private Equity
Geography
- United Kingdom – Catapult Ventures Group is a UK-based private equity firm, relevant due to their investment in Monument Therapeutics.
Industry
- Biotechnology – Monument Therapeutics operates in the biotechnology sector, focusing on precision neuroscience to develop treatments for central nervous system disorders.
- Private Equity – Catapult Ventures Group, involved in the appointments, is a private equity firm investing in healthcare and other innovative sectors.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Monument Therapeutics | Target Company | Company | A precision neuroscience company developing treatments for CNS disorders. |
| Catapult Ventures Group | Private Equity Firm | Company | A private equity firm supporting Monument Therapeutics through strategic appointments. |
| Robert S. Radie | Non Executive Chair | Person | Appointed as the Non Executive Chair at Monument Therapeutics, bringing his biotech expertise. |
| Heather Preston | Advisory Board Member | Person | Joined the Advisory Board at Monument Therapeutics, contributing with her healthcare and investment background. |